Time Room

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing Elevidis Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients – Sarepta Therapeutics & more related News Here

Time Room
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing Elevidis Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients – Sarepta Therapeutics & more related News Here

  1. Sarepta announced positive topline three-year EMBARK results, showing that Alevidis significantly slowed disease progression on key functional measures in ambulatory Duchenne patients.Sarepta Therapeutics
  2. Sarepta’s DMD gene therapy drives disease remission three years after treatmentbiospace
  3. Sarepta’s Duchenne gene therapy slows disease progression in three yearsreuters
  4. Sarepta Therapeutics will report 3-year topline data from the EMBARK study of Alevidis gene therapy in ambulatory individuals with Duchenne muscular dystrophy.business wire
  5. Sarepta stock soars. 3-year study results bring hope for Elevidis.Baron’s
Exit mobile version